The surgeon describes facial volume loss and sagging after major weight loss, including on GLP-1s, and says they assess both tissue descent and lost volume.
Recap by typeshit. Post by @suleplasticsurgery on Instagram.
15:25
Doctor Alex says Ozempic works but comes with a catch, and walks through what he thinks people misunderstand about GLP-1 drugs.
Lilly reports on Oct. 29, and Zacks expects investors to focus on Foundayo after the oral GLP-1 brought in $98 million in its first full quarter on sale.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
Smaller portions could become more common on shelves, with inflation and GLP-1 appetite changes both pushing food makers toward personal packs.
A short look at two next-wave obesity drugs, retatrutide and CagriSema, and where they stand heading into 2026.
The telehealth company's press release says the price stays flat as doses rise, billed $375 per quarter. Compounded versions are not FDA approved, the release notes.
Loading…